Eupraxia Pharmaceuticals Inc. Announces Voting Results from Annual General and Special Meeting of Shareholders

VICTORIA, British Columbia, June 02, 2025 — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in pharmaceutical development, has announced the results from its Annual General and Special Meeting of Shareholders held on June 2, 2025. The company, based in Victoria, Canada, is known for its innovative DiffuSphere™ technology, which aims to optimize drug delivery for applications with significant unmet needs.

During the meeting, a resolution was passed by ballot vote, resulting in the election of all six nominees proposed by management for the Company’s board of directors. These nominees were listed in the Company’s Management Information Circular dated April 25, 2025. The newly elected directors will serve until the next annual meeting of shareholders or until their successors are elected or appointed.

Eupraxia Pharmaceuticals Inc. operates in the health care sector and is listed on the Toronto Stock Exchange. As of May 29, 2025, the company’s close price was CAD 5.34, with a 52-week high of CAD 6.49 on February 25, 2025, and a 52-week low of CAD 3.07 on October 21, 2024. The company’s market capitalization stands at CAD 184,980,000, and it has a price-to-earnings ratio of -5.15.

The company continues to focus on developing pharmaceuticals for long-lasting treatments while minimizing safety complications in both target and non-target tissues. Eupraxia serves patients in Canada and provides more information about its products and services on its website at www.eupraxiapharma.com .